Literature DB >> 28108233

Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis.

Eva-Carina Heier1, Anna Meier1, Henrike Julich-Haertel1, Sonja Djudjaj2, Monica Rau3, Thomas Tschernig4, Andreas Geier3, Peter Boor2, Frank Lammert1, Veronika Lukacs-Kornek5.   

Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver (NAFL) is the hepatic consequence of metabolic syndrome and can progress to non-alcoholic steatohepatitis (NASH). The identification of molecular and cellular factors that determine the progression of NASH and lead to irreversible hepatocellular damage are crucial. Dendritic cells (DCs) represent a heterogeneous cell population among which CD103+ DCs play a significant role in immunity and tolerance. We aimed to clarify the role of this DC subset in the pathomechanism of NASH.
METHODS: Steatosis progression towards steatohepatitis was analysed using multicolor FACS analyses, cytokine and qPCR array in high sucrose diet (HSD) and methionine and choline deficient diet (MCD) fed wild-type and basic leucine zipper transcription factor, ATF-Like-3 (Batf3) deficient animals, which lack CD103+ DCs (classical type-1 DC, cDC1s).
RESULTS: Metabolic challenge of Batf3-/- animals resulted in the progression of steatosis towards steatohepatitis, manifesting by an increased influx of inflammatory cells into the liver and elevated inflammatory cytokine production of myeloid cells upon innate stimuli. However, the lack of cDC1s did not affect cellular apoptosis and fibrosis progression but altered genes involved in lipid metabolism. The adoptive transfer of CD103+ cDC1s to Batf3 deficient animals reversed these observed changes and more importantly could attenuate cellular damage and inflammation in established murine steatohepatitis.
CONCLUSION: Here, we have identified the murine CD103+ cDC1s as a protective DC subtype that influences the pro-anti-inflammatory balance and protects the liver from metabolic damage. As guardians of liver integrity, they play a key role in the inflammatory process during the development of steatohepatitis in mice. LAY
SUMMARY: Non-alcoholic fatty liver (NAFL) is the hepatic consequence of metabolic syndrome and can lead to non-alcoholic steatohepatitis (NASH). The current study demonstrated that a specific murine dendritic cell subtype possesses a potent regulatory role to influence the inflammatory milieu of the liver in this process.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dendritic cells; Inflammation; NASH; Steatosis

Mesh:

Substances:

Year:  2017        PMID: 28108233     DOI: 10.1016/j.jhep.2017.01.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

Review 1.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

Review 2.  Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.

Authors:  Ki Wung Chung; Ye Eun Cho; Seung-Jin Kim; Seonghwan Hwang
Journal:  Arch Pharm Res       Date:  2022-04-07       Impact factor: 4.946

Review 3.  Understanding the cellular interactome of non-alcoholic fatty liver disease.

Authors:  Sebastian J Wallace; Frank Tacke; Robert F Schwabe; Neil C Henderson
Journal:  JHEP Rep       Date:  2022-06-15

Review 4.  Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase.

Authors:  Niharika Samala; Sarah A Tersey; Naga Chalasani; Ryan M Anderson; Raghavendra G Mirmira
Journal:  J Diabetes Complications       Date:  2017-07-31       Impact factor: 2.852

5.  XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis.

Authors:  Assaf Weiner; Ziv Ben-Ari; Mathias Heikenwälder; Eran Elinav; Ido Amit; Aleksandra Deczkowska; Eyal David; Pierluigi Ramadori; Dominik Pfister; Michal Safran; Baoguo Li; Amir Giladi; Diego Adhemar Jaitin; Oren Barboy; Merav Cohen; Ido Yofe; Chamutal Gur; Shir Shlomi-Loubaton; Sandrine Henri; Yousuf Suhail; Mengjie Qiu; Shing Kam; Hila Hermon; Eylon Lahat; Gil Ben Yakov; Oranit Cohen-Ezra; Yana Davidov; Mariya Likhter; David Goitein; Susanne Roth; Achim Weber; Bernard Malissen
Journal:  Nat Med       Date:  2021-05-20       Impact factor: 53.440

6.  Co-Stimulation-Impaired Bone Marrow-Derived Dendritic Cells Prevent Dextran Sodium Sulfate-Induced Colitis in Mice.

Authors:  Carl Engman; Yesica Garciafigueroa; Brett Eugene Phillips; Massimo Trucco; Nick Giannoukakis
Journal:  Front Immunol       Date:  2018-05-03       Impact factor: 7.561

Review 7.  Adaptive immunity: an emerging player in the progression of NAFLD.

Authors:  Salvatore Sutti; Emanuele Albano
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10-11       Impact factor: 46.802

Review 8.  The Role of Myeloid-Derived Cells in the Progression of Liver Disease.

Authors:  Chris John Weston; Henning Wolfgang Zimmermann; David H Adams
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

Review 9.  Stress kinases in the development of liver steatosis and hepatocellular carcinoma.

Authors:  Beatriz Cicuéndez; Irene Ruiz-Garrido; Alfonso Mora; Guadalupe Sabio
Journal:  Mol Metab       Date:  2021-02-13       Impact factor: 7.422

10.  Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs-mediated CD8+ T cell responses.

Authors:  Fuping Zhang; Chengshi Wang; Xin Wen; Yang Chen; Ruiwen Mao; Danli Cui; Lan Li; Jingping Liu; Younan Chen; Jingqiu Cheng; Yanrong Lu
Journal:  J Cell Mol Med       Date:  2020-04-13       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.